Helix Biomedix to focus on commercialisation, loses CSO
This article was originally published in Scrip
Helix Biomedix of the US is shifting its focus from expanding its libraries of bioactive peptides and small molecules to "intensifying" efforts to commercialise them. As a result, the company's CSO Dr Timothy Falla is leaving his post.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.